INCB18424: Phase III started

Incyte and Novartis began the open-label, international Phase III RESPONSE trial to compare twice-daily 10 mg INCB18424 vs. best available therapy in about 300 patients with PV who are resistant to or intolerant of hydroxyurea. The start of the trial triggers a $50 million milestone payment to Incyte from Novartis under a 2009 deal granting the pharma exclusive rights to the compound outside the U.S. (see BioCentury, Dec. 7, 2009). ...